SPECIFIC KILLING OF CYTOTOXIC T CELLS AND ANTIGEN-PRESENTING CELLS BY CD4+ CYTOTOXIC T CELL CLONES

A Novel Potentially Immunoregulatory T-T Cell Interaction in Man

By TOM H. M. OTTENHOFF AND TUNA MUTIS

From the Department of Immunohaematology and Blood Bank, University Hospital, 2300 RC Leiden, The Netherlands

Resistance to intracellular microorganisms such as mycobacteria is dependent on antigen-specific MHC class II–restricted helper T cells (Th) (1). Th cells are thought to release macrophage-activating factors that enable macrophages to eliminate the infectious organism (1). It has recently become clear, however, that exposure to intracellular parasites not only induces a Th cell but also a CTL response. CTL may be important effector cells in the protective immune response to these parasites (reviewed in reference 2). For example, Mycobacterium leprae and M. bovis BCG are potent inducers of antigen-specific HLA-restricted CTL that lyse human macrophages (3, 4). These CTL can belong to both the CD8+ and the CD4+ subset, and are readily detectable after primary in vitro exposure of PBMC to antigen (3, 4, Birhane Kale Ab, R. Kiesstling, P. Converse, E. Halapi, G. Tadesse, and T. H. M. Ottenhoff, manuscript submitted for publication). We have also shown that the 65-kD mycobacterial heat shock protein (hsp) is an important target antigen for polyclonal CD4+ HLA-DR-restricted CTL (3, 5).

CTL lyse target cells that express the ligand for the TCR, i.e., a peptide fragment of antigen complexed to an MHC molecule (6, 7). Such antigen fragments are produced by the processing machinery of the target cell, and can often be replaced by synthetic peptides (7). Thus, target cells become susceptible to CTL-mediated lysis upon incubation with exogenous, “preprocessed” peptide antigen in vitro. CTL lyse target cells through a complex mechanism, that may involve the release of cytotoxic granules that contain lytic effector molecules like perforin, serine esterases, and various other mediators, but also granule exocytosis-independent lytic pathways have been described (reviewed in references 8, 9). In either case, however, CTL were found to be remarkably resistant against lysis by themselves (8–10), by other primary (11) or cloned (8–10, 12–15) CTL, by purified granules (11, 14–16), and by purified perforin itself (17, 18). Most studies addressing this CTL resistance to lysis have been performed with mouse CD8+ CTL.

This study was supported by the Dutch Organization for Scientific Research, by the Immunology of Leprosy Component of the World Health Organization and by the European Community.

Address correspondence to Dr. Tom H. M. Ottenhoff, Department of Immunohaematology and Blood Bank, University Hospital Building 1, E3-Q, P. O. Box 9600, 2300 RC Leiden, The Netherlands.

Abbreviations used in this paper: CS, circumsporozoite antigen; hsp, heat shock protein.

J. Exp. Med. © The Rockefeller University Press • 0022-1007/90/06/2011/14 $2.00
Volume 171 June 1990 2011-2024
We have now further characterized the CTL response against the mycobacterial 65-kD hsp. We found that the mycobacterial 65-kD hsp triggers CD4+ CTL clones that are specific for different peptide defined epitopes (19, 20). These CTL not only lyse APCs but also CD4+ or CD8+ CTL clones, including themselves, that carry the proper peptide/HLA class II complex. CD4+ CTL are therefore not by definition resistant to CTL- or self-mediated lysis; in addition, CTL-mediated CTL lysis may represent a novel immunoregulatory pathway in man, since human T cells, in contrast to murine, express MHC class II.

Materials and Methods

Antigens. The recombinant 65-kD hsp of M. bovis BCG was a gift of Dr. J. D. A. van Embden (Bilthoven, The Netherlands). Peptides of the M. leprae 65-kD hsp were made by solid-phase peptide synthesis and checked by analytical reverse-phase HPLC and amino acid analysis as described previously (20), and were a kind gift of Dr. D. C. Anderson (Seattle, WA). The Plasmodium falciparum CS peptide was a gift of Dr. F. Sinigaglia (Basel, Switzerland) (21). The sequences of the peptides are given in Table I.

T Cell Clones. The T cell clones used in this study are summarized in Table I. Some of them have been described previously with regard to their antigen specificity and HLA class II restriction (19, 20, 22-24).

Cytotoxicity Assay. After overnight pulsing with antigen (5 μg/ml), target cells were pelleted, resuspended, and labeled with 100 μCi 3HCr sodium chromate (Amersham International, Amersham, UK) during 1 h at 37°C. After three washes, target cells were added to 96-well round-bottomed plates (Costar 3799) in 100 μl of medium at 10^6 cells/well in triplicate wells. Effector cells were then added in 100 μl at the indicated E/T cell ratios. The plates were incubated for 4 h and then centrifuged, after which cell-free supernatants were collected from each well, and 3HCr release was counted in a gamma counter. The percent specific lysis was calculated using the following formula: percent specific lysis = [(experimental release - spontaneous release)/(maximal release - spontaneous release)] x 100%. All cultures were set up in Iscove’s modified Dulbecco’s Medium (Gibco Laboratories, Grand Island, NY) supplemented with penicillin (100 μg/ml), streptomycin (100 μg/ml) (both Gibco Laboratories, Grand Island, NY) and 10% pooled human AB serum.

Results

65-kD hsp or CS Peptide-dependent Lysis of EBV-BLCL Targets by CD4+ Cytotoxic T Cell Clones. Peptide pulsed or nonpulsed HLA class II matched EBV-BLCL cells were used as target cells for freshly cultured CD4+ HLA class II–restricted T cell clones that recognized specific peptides of the mycobacterial 65-kD hsp (see Table I). As shown in Fig. 1, all clones strongly lysed target cells pulsed with the specific peptide but not targets pulsed with irrelevant or no peptide. A control P. falciparum CS peptide-specific CD4+ T cell clone, MGD5, was included that gave similar results. Thus, T cell clones that recognize different peptides in combination with DR or DO restriction elements and that are derived from different individuals, are cytotoxic for peptide-pulsed target cells.

Clones NIC8 and W2G2 were able to lyse EBV-BLCL that had been pulsed with the purified, whole recombinant 65-kD hsp. Clone R1F9 showed minimal lysis and the other clones no lysis at all of recombinant 65-kD hsp pulsed EBV-BLCL. Since these latter clones are able to lyse macrophages under similar conditions (data not shown), these results point to a relative presentation defect of these EBV-BLCL to some of the 65-kD hsp–specific T cell clones. This defect is apparently overcome when peptide is used instead of the recombinant 65-kD molecule.
| Pathogen | Protein | Position | Sequence (one-letter amino acid code) | Recognized by T cell clone | Restricted by |
|----------|---------|----------|---------------------------------------|--------------------------|--------------|
| *M. leprae* | 65-kD hsp | 3-28 | KTIAYDEARRGLERGLLNLVADAVK | R1F9 | HLA-DR3 |
|          |        | 3-13 | KTIAYDEARR | R1F9 | HLA-DR3 |
|          |        | 183-204 | LQELTEGMRDFKGYISGYFVT | R3F10 | HLA-DQ |
|          |        | 412-425 | GGGVTLQAAPALD | W2G2, N3A9, N1C8 | HLA-DR1 |
|          |        | 416-439 | TLLQAAPALDKLKLRTGDEATGANI | R2F10, RP121-2 | HLA-DR2 |
|          |        | 418-427 | LQAAPALDK | R2F10, RP121-2 | HLA-DR2 |
| *P. falciparum* | CS | 378-398 | DIEKKIAKMEKASSVFNVNS | MGD5 | HLA-DR2 |
FIGURE 1. 65-kD hsp or CS peptide-specific lysis of EBV BLCL targets by CD4⁺ cytotoxic T cell clones. CD4⁺ effector T cell clones were added to target cells at the indicated E/T ratios. Target cells were HLA class II matched or autologous EBV- BLCL (10⁴ cells/well) that had been pulsed with antigen during 18 h before the 4-h ^5¹Cr-release assay. Antigens are indicated by the following symbols: ( ) 416-439 peptide of 65-kD hsp, (O) 183-204 peptide of 65-kD hsp, (■) 3-28 peptide of 65-kD hsp, (○) 412-425 peptide of 65-kD hsp, (□) r65kD hsp, (*) 378-398 peptide of CS, (▲) no antigen.

One representative experiment (Table II) shows that the level of target cell lysis is dependent on the peptide concentration during the pulsing phase. This further underlines the antigen dependency and specificity of target cell lysis by CD4⁺ clones.

CD4⁺ 65-kD hsp-specific CTL Lyse Themselves and Other CD4⁺ CTL in the Presence of Specific Peptide. Human T cell clones, in contrast to mouse T cells, strongly express MHC class II antigens. Synthetic peptides can bind directly to MHC class II. Since CTL usually are resistant to lysis by self- or other CTL or subcellular CTL components, we investigated if peptide pulsed CTL would be susceptible to CTL-mediated lysis. The results in Table III, A and B show that all 65-kD hsp-specific CTL clones lyse themselves as well as other autologous T cell clones that had been pulsed with relevant peptide. Both TCR-α/β and TCR-γ/δ cells (data not shown) are susceptible to lysis. In contrast, an HLA mismatched clone (SCL 5.12, Table IIIA) is not lysed.

Although EBV-BLCL can present (probably processed) native recombinant 65-kD hsp to some T cell clones (W2G2, NiC8; Table IIIB), T cell clones are unable to do so (Table IIIB).

So far, all tested 65-kD hsp peptide-specific CD4⁺ T cell clones are able to lyse CD4⁺ CTL in the presence of appropriate peptide. Thus, our results show that peptide-specific CD4⁺ CTL are able to lyse themselves as well as other CD4⁺ CTL in the presence of specific peptide.
Table II
Peptide Concentration Dependency of Target Cell Lysis

| Target cell | Pulsed with 65-kD hsp peptide | Effector: R1F9 |
|-------------|-------------------------------|----------------|
| EBV-BLCL    | 3-12 0.005 µg/ml              | 0 0 0 0       |
|             | 3-12 0.05 µg/ml               | 9 4 3 0       |
|             | 3-12 0.5 µg/ml                | 21 11 3 0     |
|             | 3-12 5.0 µg/ml                | 39 33 19 16   |
|             | 418-427 5.0 µg/ml             | 73 56 23 6    |

Target cells were incubated with the indicated peptide concentrations for 18 h before labeling with $^{51}$Cr. Assays were set up in triplicate with $10^4$ target cells per well. Effector cells were added to wells at the indicated E/T cell ratios. $^{51}$Cr release in culture supernatants was determined after 4 h. Results are expressed as percent specific lysis.

$CD4^+ \ 65$-kD hsp Peptide-specific CTL Lyse HLA Class II Compatible CD8$^+$ CTL Clones in the Presence of Specific Peptide. Since most studies addressing the resistance of CTL against self-mediated killing have focused on the "classical" CD8$^+$ CTL, we tested four randomly selected HLA class II compatible CD8$^+$ CTL clones, specific for HLA class I/minor transplantation antigens (6, 25, 26). CTL C754.5w4 could only be lysed by effector CTL R2F10 but not R1F9, as expected on the basis of its HLA DR phenotype (Table IV). The other three CD8$^+$ CTL clones could be lysed by both CD4$^+$ CTL clones, provided that they had been pulsed with the proper 65-kD peptide. The levels of lysis were much lower than those seen with EBV-BLCL targets, suggesting a partial but not total protection from CTL-mediated lysis. Thus, peptide-pulsed human CD8$^+$ cytolytic CTL clones can be lysed by CD4$^+$ CTL clones, and therefore are not absolutely resistant against CTL-mediated lysis.

$CD4^+$ CTL-mediated Lysis Does Not Induce Nonspecific Bystander Lysis. CD4$^+$ T cell clones have been reported to acquire nonspecific lytic activity upon long-term culture in IL-2. Although we found no evidence for nonspecific lysis, we tested whether the presence of a high dose of rIL-2 in the assay could trigger such nonspecific lysis. Lysis remained completely specific in the presence of excess rIL-2 (100 U/ml) or after overnight preincubation of target cells with an excess rIFN-γ (250 U/ml) (data not shown).

In Table V, subsequent experiments are shown in which unlabeled (cold) antigen-pulsed targets were mixed with $^{51}$Cr-labeled (hot) unpulsed targets in order to exclude nonspecific bystander lysis. The three experiments show that CTL strongly lyse hot, peptide-pulsed EBV-BLCL. When peptide pulsed targets were added as cold targets to nonpulsed hot targets, the lysis of the former did not induce significant lysis of the latter, bystander targets. Three cold targets were tested: EBV-BLCL, K562 (a human NK target), and a CTL clone. Other experiments showed that killing was an active, temperature- and contact-dependent process, including Ca$^{2+}$ influx in CTL immediately upon activation by target cells (not shown). Thus, the effector phase of lysis by CD4$^+$ CTL is entirely specific and does not induce bystander lysis.

Cold Target Competition Experiments. To further confirm the specificity of lysis, cold target competition experiments were carried out. Fig. 2 gives one representative ex-
CD4⁺ CYTOTOXIC T CELL CLONES

### Table III
Antigen-specific Lysis of CD4⁺ T Cells by CD4⁺ CTL Reactive with 65-kD hsp of Mycobacteria

| Target cell | Pulsed with 65-kD hsp peptide | Effector cells | R1F9 | R2F10 | RP171-2 |
|-------------|--------------------------------|----------------|-------|-------|---------|
|             |                               | E/T:           | 100:1 | 25:1  | 6:1     |
| EBV-BLCL    | 3-28                           |                | 89    | 78    | 36      |
|             | 416-439                        |                | 0     | 3     | 87      |
|             |                                |                | 0     | 0     | 1       |
| R1F9        | 3-28                           |                | 82    | 50    | 42      |
|             | 416-439                        |                | 0     | 0     | 90      |
|             |                                |                | 0     | 0     | 0       |
| R2F10       | 3-28                           |                | 68    | 60    | 50      |
|             | 416-439                        |                | 5     | 11    | 0       |
|             |                                |                | 0     | 0     | 0       |
| RP171-2     | 3-28                           |                | 84    | 88    | 49      |
|             | 416-439                        |                | 4     | 0     | 0       |
|             |                                |                | 0     | 0     | 0       |
| SCL5.12*    | 3-28                           |                | 3     | 4     | 1       |
|             | 416-439                        |                | 0     | 0     | 0       |
|             |                                |                | 3     | 2     | 0       |

| Effector cells | W2G2 | N1G8 | N3A9 |
|----------------|------|------|------|
| E/T: 100:1 25:1 6:1 | 100:1 25:1 6:1 | 100:1 25:1 6:1 |
| EBV-BLCL r65 kD hsp | 42 | 30 | 28 |
| 412-425        | 82 | 62 | 68 |
|                | 0  | 0  | 1  |
| W2G2 r65 kD hsp | ND | ND | ND |
| 412-425        | 60 | 80 | 53 |
|                | 0  | 7  | 0  |
| N1G8 r65 kD hsp | 0  | 0  | 0  |
| 412-425        | 27 | 36 | 24 |
|                | 0  | 2  | 3  |
| N3A9 r65 kD hsp | 0  | 0  | 0  |
| 412-425        | 50 | 35 | 59 |
|                | 0  | 6  | 6  |

Effector: R3F10

| E/T: 100:1 25:1 6:1 | 100:1 25:1 6:1 |
|----------------------|----------------|
| EBV-BLCL 3-28        | 3   | 7   | 0  |
| 183-204              | 65  | 34  | 15 |
| R3F10 3-28           | 0   | 0   | 0  |
| 183-204              | 51  | 37  | 0  |
| RP171-2 3-28         | 0   | 0   | 0  |
| 183-204              | 39  | 35  | 0  |

Target cells were incubated with 5 μg/ml of the indicated antigens for 18 h before labeling with ⁵¹Cr (see footnote to Table II). The results are expressed as percent specific release.

* HLA mismatched clone.
Target cells were pulsed overnight with 5 μg/ml of the indicated peptides. Assays were set up in triplicate with 10^4 target cells per well. Effector cells were added to wells at the indicated E/T cell ratios. ^51Cr release in culture supernatants was determined after 4 h. Results are expressed as percent specific lysis.

Table IV

| Target cell    | HLA-DR type | Pulsed with 65-kD hsp peptide | CD4+ effector cells |
|----------------|-------------|-------------------------------|---------------------|
|                |             |                               | R1F9 100:1 25:1 50:1| R2F10 100:1 25:1 50:1|
| EBV-BLCL       | 2,3         | 3-28                           | 88 64 24 0 6 6    |
|                |             | 416-439                         | 2 0 3 86 64 53    |
|                |             | -                              | 4 2 0 3 5 3      |
| CD8+ CTL       | 3-28         | 2                              | 1 2 2 0 1 1      |
| Wam C754 SW4   | 1,2         | 416-439                         | 0 0 1 24 20 13    |
|                |             | -                              | 0 0 0 0 0 2      |
| CD8+ CTL       | 3-28         | 2                             | 23 33 19 0 0 7   |
| Hel 1E6        | 2,3         | 416-439                         | 0 3 3 29 23 20   |
|                |             | -                              | 1 5 5 0 5 8      |
| CD8+ CTL       | 3-28         | 11                             | 11 13 10 0 2 6   |
| Hel 5H4        | 2,3         | 416-439                         | 1 0 3 28 36 15   |
|                |             | -                              | 2 2 4 1 0 4      |
| CD8+ CTL       | 3-28         | 36                             | 36 15 12 0 5 6   |
| Hel 1E4        | 2,3         | 416-439                         | 0 2 6 28 25 38   |
|                |             | -                              | 0 0 0 0 0 0      |

Lysis of CD8+ CTL Clones by CD4+ CTL Clones

example. Lysis of peptide-pulsed EBV-BLCL could be competed away in a dose-dependent fashion by cold EBV-BLCL that had been pulsed with the same peptide (Fig. 2A) but not by the nonpulsed cold target (Fig. 2B). Peptide-pulsed but not unpulsed EBV-BLCL were very efficient in competing away lysis of peptide pulsed CTL targets: (Fig. 2, C and D). When peptide-pulsed or nonpulsed CTL were used as cold competitors for peptide-pulsed EBV-BLCL, a very high spontaneous release was observed because, as expected, these cold CTL efficiently lysed peptide pulsed EBV-BLCL (data not shown).

Similar data were obtained for another CTL clone. Thus, although CD4+ CTL efficiently lyse peptide-pulsed CTL targets, they bind more efficiently to EBV-BLCL targets. This may also explain the often lower levels of lysis that are observed with CTL as compared with EBV-BLCL targets (see Table III, A and B).

Effect of Target Cell or Effector Cell Prepulsing with Peptide. We next tried to replace the prepulsing of target cells with peptide by adding free peptide into the assay. Even very high peptide concentration (up to 100 μg/ml) gave suboptimal lysis as compared with lysis of targets that had been pulsed overnight (5 μg/ml) (not shown). This was unexpected since in other studies, the addition of free (tetanus toxoid) peptide to EBV-BLCL led to an almost immediate Ca^{2+} influx in an antigen-specific CD4+ T cell clone (27). Besides considering other explanations (the slow HLA-peptide complex formation [28]; the higher complexity of target cell lysis as compared with merely TCR/CD3 signaling; the induction of peptide-dependent self-mediated CTL killing in the presence of the free peptide), we tested whether the direct binding of free peptide to the TCR possibly interfered with (or led to) target
**Table V**

**CD4+ CTL Lyse Target Cells in the Absence of Bystander Lysis**

| Exp. | Hot target pulsed with 65-kD hsp peptide | Cold target pulsed with 65-kD hsp peptide | Effector cells |
|------|----------------------------------------|------------------------------------------|---------------|
|      |                                        |                                          | R2F10         |
|      |                                        |                                          | RP171-2       |
|      |                                        |                                          | R1F9          |
| 1    | BLCL + 3-28                            | -                                        | 100:1 25:1 6:1| 100:1 25:1 6:1| 100:1 25:1 6:1|
|      | BLCL + 416-439                         | -                                        | 0 0 0         | 87 98 85 61 66 25 0 0 3 |
|      | BLCL unpulsed                          | -                                        | 1 0 0         | 7 2 0 0 0 0 0 0 0 |
|      | BLCL unpulsed BLCL + 3-28              | ND ND ND                                  | 16 5 3 18 11 2| 7 2 0 0 ND ND ND |
|      | BLCL unpulsed BLCL + 416-439           | ND ND ND                                  | 16 5 3 18 11 2| 7 2 0 0 ND ND ND |
| 2    | BLCL + 416-439                         | -                                        | 97 82 48      | 0 0 0 |
|      | BLCL unpulsed                          | -                                        | 0 0 0         | 0 0 0 |
|      | K562 BLCL + 416-439                    | 0 5 0                                    | 5 1 0         | 0 0 0 |
| 3    | BLCL + 3-12                            | -                                        | 80 39 8       | 0 4 2 |
|      | BLCL unpulsed                          | -                                        | 0 4 2         | 0 4 2 |
|      | R1F9 + 3-12                            | 56 37 16                                 | 0 4 ND        | 0 0 0 |
|      | R1F9 unpulsed                          | 0 6 0                                    | 1 3 1         | 0 0 0 |
|      | BLCL unpulsed BLCL + 3-12              | 1 3 1                                    | 0 4 ND        | 0 0 0 |
|      | BLCL unpulsed R1F9 + 3-12              | 0 4 ND                                   | 0 0 0         | 0 0 0 |
|      | R1F9 unpulsed BLCL + 3-12              | 0 0 0                                    | 0 0 0         | 0 0 0 |
|      | R1F9 unpulsed R1F9 + 3-12              | 0 0 0                                    | 0 0 0         | 0 0 0 |

Target cells were preincubated with or without peptide and used as ³¹Cr labeled (hot) or unlabeled (cold) targets. Experiments were set up in triplicate wells to which 10⁴ hot and if indicated 10⁴ cold targets were added. Effector cells were then added at the indicated E/T (hot) ratios. ³¹Cr release in the supernatants was determined after 4 h. Results are expressed as percent specific lysis.

Cell killing. Effector cells were preincubated overnight with peptide and then added to peptide pulsed or nonpulsed target cells (Table VI). The preincubation of CTL did not result in lysis of unpulsed EBV-BLCL, suggesting that the formation of a functional TCR-peptide-MHC complex did not take place under these conditions. Lysis of peptide-pulsed target cells was not abrogated, showing that CTL peptide pretreatment did not block TCR-mediated recognition of MHC bound peptide. On the other hand, quantitative differences were observed: at higher E/T ratios, less efficient killing by pretreated CTL was seen, probably as a result of "cold effector" competition with peptide pulsed targets. At lower E/T ratios, killing was enhanced rather than inhibited. This could be accounted for by the preactivation of CTLs by peptide, and based on the above results, is not a consequence of enhanced TCR-antigen-MHC complex formation by TCR-bound free peptide.

**Discussion**

Until recently, cell-mediated immunity to intracellular organisms was thought to depend exclusively on CD4⁺ antigen-specific helper T lymphocytes: upon acti-
Figure 2. Inhibition of peptide-specific hot target cell lysis by peptide-pulsed or unpulsed cold target cells. Target cells were pulsed with 65-kD hsp peptide 3–12 (5 μg/ml) for 18 h. 5 x 10^5 ^11Cr-labeled target cells were mixed with unlabeled cold target cells at different cold/hot target ratios: (□) 50:1, (▲) 15:1, (●) 5:1, (●) no cold target added. T cell clone R1F9 was used as effector cell in the experiment shown and added into wells at the indicated effector/hot target ratios. ^11Cr release in the culture supernatants was assessed after 4 h incubation. (A) Hot target: EBV-BLCL pulsed with peptide 3–12, Cold target: EBV-BLCL pulsed with peptide 3–12; (B) Hot target: EBV-BLCL pulsed with peptide 3–12, Cold target: EBV-BLCL not pulsed; (C) Hot target: R1F9 pulsed with peptide 3–12, Cold target: EBV-BLCL pulsed with peptide 3–12; (D) Hot target: R1F9 pulsed with peptide 3–12, Cold target: EBV-BLCL not pulsed.

![](image1)

| Table VI |
| --- |
| **Effect of Peptide Preincubation of Effector Cells on Antigen-specific Lysis of Target Cells** |

| Target cell | Pulsed with 65-kD hsp peptide | Preincubated with: | Effector: R1F9 |
| --- | --- | --- | --- |
| | | | No peptide | 65-kD hsp peptide 3–28 |
| | | E/T: 100:1 | 25:1 | 6:1 | 2:1 | 100:1 | 25:1 | 6:1 | 2:1 |
| EBV-BLCL | 3–28 | 100 | 96 | 43 | 14 | 54 | 49 | 64 | 44 |
| EBV-BLCL | 416-439 | 0 | 0 | 2 | 1 | 10 | 10 | 7 | 5 |
| EBV-BLCL | – | 9 | 8 | 0 | 0 | 0 | 0 | 2 | 0 |

| Target cell | Pulsed with 65-kD hsp peptide | Preincubated with: | Effector: R2F10 |
| --- | --- | --- | --- |
| | | | No peptide | 65-kD hsp peptide 416-439 |
| | | E/T: 100:1 | 25:1 | 6:1 | 2:1 | 100:1 | 25:1 | 6:1 | 2:1 |
| EBV-BLCL | 3–28 | 0 | 3 | 0 | 1 | 9 | 4 | 0 | 0 |
| EBV-BLCL | 416-439 | 79 | 20 | 22 | 17 | 35 | 69 | 63 | 23 |
| EBV-BLCL | – | 0 | 4 | 7 | 2 | 9 | 0 | 0 | 6 |

Target cells or effector cells were preincubated with 5 μg/ml of the indicated antigens for 18 h and then washed three times. Assays were set up in triplicate (10^5 cells/well). The results are expressed as percent specific lysis.
antigen-specific, HLA-restricted CD4+ and CD8+ CTLs, as well as antigen non-specific unrestricted killer cells (3-5). Each of these effector cells lysed macrophages. Recent studies in which rIL-2, rIFN-γ, or purified protein derivative (PPD) was injected into lepromatous leprosy patients' skin (29-31), and other studies in which in situ hybridization techniques were used (32) have also indirectly supported an important role for cytotoxic T cells in leprosy. Based on these new findings, the classical concept of cell-mediated immunity needs to be reconsidered, since it has become apparent that not only "macrophage-help" but also "macrophage-lysis" may be an effector mechanism in the cellular immune response to mycobacteria. We therefore wanted to gain further insight into the antigen specificity and function of CTL directed towards mycobacterial pathogens. We have demonstrated earlier that the mycobacterial 65-kD hsp is an important target antigen for CD4+ CTL (3,5). These CTL were readily detectable after a single antigen exposure in vitro.

We have now analyzed the CTL response to this immunodominant antigen, using a panel of CTL clones. These CD4+ CD8- CTL recognize M. leprae 65-kD hsp peptides presented by HLA class II molecules and display strong cytotoxic activity towards specific peptide-pulsed EBV-BLCL target cells. Further experiments have extended these results to macrophages as target cells (data not shown). At least four different 65-kD hsp epitopes are able to trigger CTLs. Lysis of target cells was entirely specific and did not result in bystander lysis of EBV-BLCL, tumor cells or other CTL clones, although the CD4+ CTL release nonspecific serine esterases upon activation (unpublished observations). As far as we are aware, this is one of the first examples of peptide-specific CTL in a human infectious disease caused by intracellular parasites. Two other recombinant M. leprae antigens carry epitopes for CD4+ cytotoxic T cell clones, namely the recombinant 18-kD antigen and a newly defined molecule, 13B3 (33). These findings are in agreement with ours, and show that also non-65-kD antigens can be recognized by CD4+ CTL. We are presently also investigating other M. leprae antigens for their ability to serve as CTL target antigens. It will also be important to correlate our findings to the capacity of these CTL to produce lymphokines, since in mice (34) and maybe also in man (36) CD4+ Th1 but not Th2 cells possess lytic potential.

An unexpected and novel finding in the present study was that CD4+ CTLs are able to lyse CD4+ or CD8- CTL clones that bear the proper HLA class II/peptide ligand. CTL are thought to be resistant to self-mediated lysis. Although during target cell killing CTL can avoid self-mediated killing by the unidirectional delivery of lytic granule compounds specifically to the target cell (36), also an active protection of CTL against lytic components has been proposed (e.g., 8-10), since CTL are unusually or sometimes even completely resistant to lysis by CTL or CTL products. For instance, cloned CTL are highly resistant to lysis by (other or self) CTL in a lectin-dependent cytotoxicity assay (14). In another study, a CTL clone efficiently lysed noncytotoxic helper T cells but only marginally lysed CTL targets, although the latter were properly recognized as evident from cold target competition experiments (12). A good correlation was found between cytotoxic capacity and resistance of CTL clones (13, 18). In contrast to their target cells, CTL themselves are highly resistant to lysis by purified CTL-derived cytotoxic granules (11, 14, 15), by highly purified perforin (17, 37). The same was found for primary, uncloned CTL (11).

It should be pointed out, however, that these studies were performed with murine
CTL that were almost always of the CD8+ phenotype. These CTL may well differ from our human CD4+ CTL. Our 65-kD hsp-specific CTL only lysed CTL targets that had been pulsed with free peptide but not with native hsp 65, suggesting that T cells do not endocytose and/or process native antigen. An exception may be antigens that specifically bind to recycling T cell membrane molecules. For instance, the gp120 HIV protein binds to CD4, is endocytosed, processed, and then presented to gp120-specific CD4+ CTL that subsequently lyse CD4+ class II+ target cells (38).

Our CTL do not give bystander lysis. This finding contrasts with the recent suggestion that activated CTL have detectable affinity for self MHC, as determined by bystander lysis of autologous or syngeneic target cells (39). Differences in target and effector cells may explain these discrepant results. Peptide preincubation of effector cells did not lead to lysis of unpulsed targets, showing that if free peptide can bind to the TCR at all, it is unable to induce the formation of a functional peptide-MHC-TCR complex. Peptide preincubation of effector cells did not also abrogate lysis of peptide preincubated target cells, but led to more efficient lysis at lower E/T ratios, probably as a result of CTL preactivation by self presentation.

What is the possible in vivo relevance of CTL-mediated T cell killing? It is conceivable that CTL that lyse M. leprae-infected macrophages, become exposed to the intracellular breakdown products of the target cell, including polypeptides of the highly abundant 65-kD hsp of the infecting organism. These peptides might then bind to class II on the CTL surface and render them targets for CTL-mediated lysis. Mycobacterial granulomas in particular may contain abundant cellular and bacterial debris including such peptides. Cytolytic T-T interactions may be involved in downregulating local T cell responses and represent a novel immunoregulatory pathway that would exclusively be found in man, since murine T cells do not express MHC class II. Human T cell clones can indeed present antigen (our unpublished observations; 40), and cytotoxic T-T cell interactions may contribute to the depletion of CD4+ T cells in HIV infections (38). Regulatory anticonotypic cytotoxic T-T cell interactions have also been described in experimental autoimmune encephalomyelitis in mice (41).

Another immunoregulatory pathway in which mycobacterial antigen-reactive CTL may be involved is the downregulation of specific B cell responses (42). Because antigen-specific B cells express specific Ig receptors, they are much more efficient in the uptake, and hence presentation of processed antigen to T cells when compared with nonspecific B cells. It is conceivable that the CTL-mediated selective killing of specific B cells may, at least in part, explain why tuberculoid leprosy patients are good CTL responders to M. leprae and have low specific antibody titers, whereas the opposite is seen in lepromatous patients.

In conclusion, we have shown that mycobacterial peptide-specific HLA class II-restricted CD4+ T cell clones display strong specific cytolytic activity towards both APCs, and, unexpectedly, CD4+ and CD8+ CTL clones, including themselves. Since, in contrast to murine T cells human T cells express class II, CTL-mediated T cell killing may represent a novel immunoregulatory pathway in man.

Summary

Mycobacterial antigens not only stimulate Th cells that produce macrophage-activating factors, but also CD4+ and CD8+ CTL that lyse human macrophages.
The mycobacterial recombinant 65-kD hsp was previously found to be an important target antigen for polyclonal CD4+ CTL. Because of the major role of 65-kD hsp in the immune response to mycobacterial as well as autoantigens, we have studied CTL activity to this protein at the clonal level. HLA-DR or HLA-DQ restricted, CD4+CD8- T cell clones that recognize different peptides of the M. leprae 65-kD hsp strongly lysed EBV-BLCL pulsed with specific but not irrelevant peptide. No bystander lysis of B cells, T cells, or tumor cells was seen. Target cell lysis could not be triggered by PMA + Ca2+ ionophore alone and depended on active metabolism. Interestingly, these CD4+ CTL also strongly lysed themselves and other HLA-class II compatible CD4+ (TCR-α/β or -γ/δ) or CD8+ CTL clones in the presence of peptide, suggesting that CTL are not actively protected from CTL-mediated lysis. Cold target competition experiments suggested that EBV-BLCL targets were more efficiently recognized than CD4+ CTL targets. These results demonstrate that hsp65 peptide-specific HLA class II-restricted CD4+ T cell clones display strong peptide-dependent cytolytic activity towards both APCs, and, unexpectedly, CD4+ and CD8+ CTL clones, including themselves. Since, in contrast to murine T cells human T cells express class II, CTL-mediated T cell killing may represent a novel immunoregulatory pathway in man.

We thank Dave Anderson for generously making available peptides of the 65-kD hsp, Els Goulmy for providing CD8+ CTL clones, Francesco Sinigaglia for providing T cell clone MGD5, Jan van Embden for providing the hsp 65, Dienne Bontrop-Elferink and Yolanthe Cornelisse for expert technical assistance, and René de Vries, Frits Koning, and Jim Kurnick for reviewing and Mariëtte Mulder for preparing the manuscript.

Received for publication 23 January 1990.

References
1. Hahn, H., and S. H. E. Kaufmann. 1981. The role of cell mediated immunity in bacterial infections. Rev. Infect. Dis. 3:1221.
2. Kaufmann, S. H. E. 1988. CD8+ T lymphocytes in intracellular microbial infections. Immunol. Today. 9:168.
3. Ottenhoff, T. H. M., B. Kale Ab, J. D. A. van Embden, J. E. R. Thole, and R. Kiessling. 1988. The recombinant 65 kilodalton heat shock protein of Mycobacterium bovis BCC/M. tuberculosis is a target molecule for CD4+ cytotoxic T lymphocytes that lyse human monocytes. J. Exp. Med. 168:1947.
4. Hancock, G. E., Z. A. Cohn, and G. Kaplan. 1989. The generation of antigen specific, major histocompatibility complex-restricted cytotoxic T lymphocytes of the CD4+ phenotype. Enhancement by the cutaneous administration of interleukin 2. J. Exp. Med. 169:909.
5. Birhane Kale Ab, Kiessling, J. D. A. van Embden, J. E. R. Thole, D. S. Kumararatne, P. Pisa, W. Wondimu, and T. H. M. Ottenhoff. 1990. Induction of antigen specific CD4+ HLA-DR restricted cytotoxic T lymphocytes as well as nonspecific nonrestricted killer cells by the recombinant mycobacterial 65 kilodalton heat shock protein. Eur. J. Immunol. In press.
6. Goulmy, E. 1985. Class I restricted human cytotoxic T lymphocytes directed against minor transplantation antigens and their possible role in organ transplantation. Prog. Allergy. 36:44.
7. Townsend, A. R. M., J. Rothbard, F. M. Gotch, G. Bahadur, D. Wraith, and A. J.
McMichael. 1986. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell. 44:959.
8. J. D.-E. Young, C.-C. Liu, P. M. Persechini, and Z. A. Cohn. 1988. Perforin dependent and independent pathways of cytotoxicity mediated by lymphocytes. Immunol. Rev. 103:161.
9. Müller-Eberhard, H. J. 1988. The molecular basis of target cell killing by human lymphocytes and of killer cell self-protection. Immunol. Rev. 103:87.
10. Young, J. D.-E. and C.-C. Lui. 1988. How do cytotoxic T lymphocytes avoid self lysis? Immunol. Today. 9:14.
11. Nagler-Anderson, C., C. Reynolds Verret, A. A. Firmenich, M. Berne, and H. N. Eisen. 1988. Resistance of primary CD8+ cytotoxic T lymphocytes to lysis by cytotoxic granules from cloned T cell lines. J. Immunol. 141:3299.
12. Kranz, D. M., and H. N. Eisen. 1987. Resistance of cytotoxic T lymphocytes to lysis by a clone of cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA. 84:3375.
13. Skinner, M., and J. Marbrook. 1987. The most efficient cytotoxic T lymphocytes are the least susceptible to lysis. J. Immunol. 159:965.
14. Blakely, A., K. Gorman, H. Ostergaard, K. Svoboda, C.-C. Liu, J. D.-E. Young, and W. R. Clark. 1987. Resistance of cloned cytotoxic T lymphocytes to cell mediated cytotoxicity. J. Exp. Med. 166:1070.
15. Gorman, K., C.-C. Liu, A. Blakely, J. D.-E. Young, B. E. Torbett, and W. R. Clark. 1988. Cloned cytotoxic T lymphocytes as target cells. Polarity of lysis revisited. J. Immunol. 141:2211.
16. Verret, C. R., A. A. Firmenich, D. M. Kranz, and H. N. Eisen. 1987. Resistance of cytotoxic T lymphocytes to the lytic effects of their granules. J. Exp. Med. 166:1536.
17. Jiang, S., P. M. Persechini, A. Zychlinsky, C.-C. Liu, B. Perussia, and J. D.-E. Young. 1988. Resistance of cytotoxic lymphocytes to perforin mediated killing. Lack of correlation with complement associated homologous species restriction. J. Exp. Med. 168:2207.
18. Liu, C.-C., S. Jiang, P. M. Persechini, A. Zychlinsky, Y. Kaufmann, and J. D.-E. Young. 1989. Resistance of cytolytic lymphocytes to perforin mediated killing. Induction of resistance correlates with increase in cytotoxicity. J. Exp. Med. 169:2211.
19. Van Schooten, W. C. A., D. G. Elferink, J. D. A. van Embden, D. C. Anderson, and R. R. P. de Vries. 1989. DR3 restricted T cells from different HLA-DR3 positive individuals recognize the same peptide (amino acids 2-12) of the mycobacterial 65 kDa heat shock protein. Eur. J. Immunol. 19:2075.
20. Anderson, D. C., W. C. A. van Schooten, M. E. Barry, A. A. M. Janson, T. M. Buchanan, and R. R. P. de Vries. 1988. A Mycobacterium leprae specific human T cell epitope crossreactive with an HLA-DR2 peptide. Science (Wash. DC). 242:259.
21. Sinigaglia, F., M. Guttering, D. Gillessen, D. M. Doran, B. Takacs, H. Matile, A. Trzeciak, and J. R. Pink. 1988. Epitopes recognized by human T lymphocytes on malaria circumsporozoite protein. Eur. J. Immunol. 18:633.
22. Ottenhoff, T. H. M., P. R. Klatser, J. Ivanyi, D. G. Elferink, M. Y. L. de Wit, and R. R. P. de Vries. 1986. Mycobacterium leprae specific protein antigens defined by cloned human helper T cells. Nature (Lond.). 319:66.
23. Ottenhoff, T. H. M., S. Neuteboom, D. G. Elferink, and R. R. P. de Vries. 1986. Molecular localization and polymorphism of HLA class II restriction determinants defined by Mycobacterium leprae reactive T cell clones from leprosy patients. J. Exp. Med. 164:1923.
24. Van Schooten, W. C. A., T. H. M. Ottenhoff, P. R. Klatser, J. Ivanyi, J. Thole, R. R. P. de Vries, and A. H. J. Kolk. 1988. T cell epitopes on the 36 k and 65 k Mycobacterium leprae antigens defined by human T cell clones. Eur. J. Immunol. 18:849.
25. Goulmy, E., J. D. Hamilton, and B. A. Bradley. 1979. Anti-self HLA may be clonally expressed. J. Exp. Med. 149:545.
26. Goulmy, E. 1988. Minor histocompatibility antigens in man and their role in transplan-
27. Roosnek, E., S. Demetz, G. Corradin, and A. Lanzavecchia. 1988. Kinetics of MHC-antigen complex formation on antigen presenting cells. *J. Immunol.* 140:4079.

28. Buus, S., A. Sette, S. M. Colon, D. M. Jenis, and H. M. Grey. 1986. Isolation and characterization of antigen-Ia complexes involved in T cell recognition. *Cell.* 47:1071.

29. Kaplan, G., R. Kiessling, Sabawork Tekleamiram, G. Hancock, G. Scheifel, C. K. Job, P. Converse, T. H. M. Ottenhoff, M. Becx-Bluemink, M. Dietz, and Z. A. Cohn. 1989. The reconstitution of cell mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin-2. *J. Exp. Med.* 169:893.

30. Nathan, C. F., G. Kaplan, W. R. Levis, A. Nusrat, M. D. Witmer, S. A. Sherwin, C. K. Job, C. R. Horowitz, R. M. Steinman, and Z. A. Cohn. 1986. Local and systemic effect of low doses of recombinant interferon-gamma after intradermal injection in patients with lepromatous leprosy. *N. Engl. J. Med.* 315:6.

31. Kaplan, G., S. Laal, G. Sheftel, A. Nusrat, I. Nath, N. K. Mathur, R. S. Mishra, and Z. A. Cohn. 1988. The nature and kinetics of a delayed immune response to purified protein derivative in the skin of lepromatous leprosy patients. *J. Exp. Med.* 169:1811.

32. Cooper, C. L., C. Mueller, T. A. Sinchaisri, C. Pirmez, J. Chan, G. Kaplan, S. M. M. Young, I. L. Weissman, B. R. Bloom, T. H. Rea, and R. L. Modlin. 1989. Analysis of naturally occurring delayed-type hypersensitivity reactions in leprosy by in situ hybridization. *J. Exp. Med.* 168:1565.

33. Mustafa, A. S., and E. Qvigstad. 1989. HLA-DR restricted antigen induced proliferation and cytotoxicity mediated by CD4+ T cell clones from subjects vaccinated with killed *M. leprae*. *Int. J. Lepr.* 57:1.

34. Cher, D. J., and T. R. Mosmann. 1987. Two types of murine helper T cell clones. II. Delayed type hypersensitivity is mediated by Th1 clones. *J. Immunol.* 138:3688.

35. Rotteveel, F. T. M., I. Kokkelink, R. A. W. van Lier, B. Kuenen, A. Meager, F. Miedema, and C. J. Lucas. 1988. Clonal analysis of functionally distinct human CD4+ T cell subsets. *J. Exp. Med.* 168:1659.

36. Peters, P. J., H. J. Geuze, H. A. van der Donk, and J. Borst. 1990. A new model for lethal hit delivery by cytotoxic T lymphocytes. *Immunol. Today.* 11:28.

37. Skinkai, Y., H. Ishikawa, M. Hattori, and K. Okumura. 1988. Resistance of mouse cytolytic cells to pore-forming protein-mediated cytolysis. *Eur. J. Immunol.* 18:29.

38. Siciliano, R. F., T. Lawton, C. Knall, R. W. Karr, P. Berman, T. Gregory, and E. L. Reinherz. 1988. Analysis of host-virus interactions in AIDS with anti gp120 T cell clones: effect of HIV sequence variation and a mechanism for CD4+ cell depletion. *Cell.* 54:561.

39. Duke, R.-C. 1989. Self recognition by T cells. I. Bystander killing of target cells bearing syngeneic MHC antigens. *J. Exp. Med.* 170:59.

40. Hewitt, C. R. A., and M. Feldman. 1989. Human T cell clones can present antigen. *J. Immunol.* 142:1429.

41. Sun, D., Y. Qin, J. Chluba, J. T. Epplen, and H. Wekerle. 1988. Suppression of experimentally induced autoimmune encephalomyelitis by cytolytic T-T cell interactions. *Nature (Lond.)*. 332:843.

42. Lanzavecchia, A. 1989. Is suppression a function of class II restricted cytotoxic T cells? *Immunol. Today.* 10:157.